Scientific article
English

Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Published in

Cancer immunology research, vol. 14, no. 1, p. 139-154

Publication date

2026-01-08

First online date

2025-10-20

Abstract

Aberrant expression of the oncogene SALL4 is associated with stemness, a more aggressive cancer phenotype, and reduced patient survival in various tumor types, making SALL4 a potential target for cancer immunotherapy. We conducted a transcriptional analysis of SALL4 expression in colorectal cancer tissues and demonstrated that SALL4 was overexpressed in primary tumors and paired liver metastases. Then, we identified the SALL4-derived S9V peptide as a naturally processed peptide that induced specific CD8+ T-cell responses from the peripheral blood of patients with gastrointestinal cancer, whereas no responses were observed in the peripheral blood of healthy donors. Thereafter, we isolated an SALL4-specific T-cell receptor (TCR) that recognized this peptide in the most common HLA molecule in the Caucasian population, HLA-A2, and used this to develop TCR-engineered T cells. In vitro analysis showed that SALL4 TCR-redirected primary CD8+ T cells exhibited cytotoxic effects against SALL4-expressing tumor cells and produced effector cytokines. In vivo, SALL4-TCR T cells significantly reduced tumor growth and improved the survival of tumor-bearing mice. Moreover, SALL4-TCR T cells displayed no toxicity against hematopoietic stem cells. Thus, we conclude that T cells engineered to express a SALL4-specific TCR have the potential to be effective as immunotherapy for solid cancers and pave the way for further clinical development.

Keywords

  • Animals
  • CD8-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / metabolism
  • Cell Line, Tumor
  • Disease Models, Animal
  • Female
  • Histocompatibility Antigens Class I / immunology
  • Humans
  • Immunotherapy / methods
  • Mice
  • Neoplasms / immunology
  • Neoplasms / therapy
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / immunology
  • Receptors, Antigen, T-Cell / metabolism
  • Transcription Factors / genetics
  • Transcription Factors / immunology
  • Transcription Factors / metabolism
  • Xenograft Model Antitumor Assays

Citation (ISO format)

BEN KHELIL, Myriam et al. Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy. In: Cancer immunology research, 2026, vol. 14, n° 1, p. 139–154. doi: 10.1158/2326-6066.CIR-24-0207

Main files (2)

Article (Published version)
Article (Accepted version)
09/01/2027

Identifiers

Journal ISSN

2326-6066
1views
0downloads

Technical informations

Creation

21/10/2026 07:43:54

First validation

17/11/2026 14:21:18

Update

17/11/2026 14:21:18

Status update

17/11/2026 14:21:18

Last indexation

17/11/2026 14:21:19
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated